Cargando…
Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
Mesoporous silicon nanoparticles (PSi NPs) are promising platforms of nanomedicine because of their good compatibility, high payload capacities of anticancer drugs, and easy chemical modification. Here, PSi surfaces were functionalized with bisphosphonates (BP) for radiolabeling, loaded with doxorub...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610067/ https://www.ncbi.nlm.nih.gov/pubmed/37896267 http://dx.doi.org/10.3390/pharmaceutics15102507 |
_version_ | 1785128164104601600 |
---|---|
author | Wen, Huang Poutiainen, Pekka Batnasan, Enkhzaya Latonen, Leena Lehto, Vesa-Pekka Xu, Wujun |
author_facet | Wen, Huang Poutiainen, Pekka Batnasan, Enkhzaya Latonen, Leena Lehto, Vesa-Pekka Xu, Wujun |
author_sort | Wen, Huang |
collection | PubMed |
description | Mesoporous silicon nanoparticles (PSi NPs) are promising platforms of nanomedicine because of their good compatibility, high payload capacities of anticancer drugs, and easy chemical modification. Here, PSi surfaces were functionalized with bisphosphonates (BP) for radiolabeling, loaded with doxorubicin (DOX) for chemotherapy, and the NPs were coated with cancer cell membrane (CCm) for homotypic cancer targeting. To enhance the CCm coating, the NP surfaces were covered with polyethylene glycol prior to the CCm coating. The effects of the BP amount and pH conditions on the radiolabeling efficacy were studied. The maximum BP was (2.27 wt%) on the PSi surfaces, and higher radiochemical yields were obtained for (99m)Tc (97% ± 2%) and (68)Ga (94.6% ± 0.2%) under optimized pH conditions (pH = 5). The biomimetic NPs exhibited a good radiochemical and colloidal stability in phosphate-buffered saline and cell medium. In vitro studies demonstrated that the biomimetic NPs exhibited an enhanced cellular uptake and increased delivery of DOX to cancer cells, resulting in better chemotherapy than free DOX or pure NPs. Altogether, these findings indicate the potential of the developed platform for cancer treatment and diagnosis. |
format | Online Article Text |
id | pubmed-10610067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106100672023-10-28 Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer Wen, Huang Poutiainen, Pekka Batnasan, Enkhzaya Latonen, Leena Lehto, Vesa-Pekka Xu, Wujun Pharmaceutics Article Mesoporous silicon nanoparticles (PSi NPs) are promising platforms of nanomedicine because of their good compatibility, high payload capacities of anticancer drugs, and easy chemical modification. Here, PSi surfaces were functionalized with bisphosphonates (BP) for radiolabeling, loaded with doxorubicin (DOX) for chemotherapy, and the NPs were coated with cancer cell membrane (CCm) for homotypic cancer targeting. To enhance the CCm coating, the NP surfaces were covered with polyethylene glycol prior to the CCm coating. The effects of the BP amount and pH conditions on the radiolabeling efficacy were studied. The maximum BP was (2.27 wt%) on the PSi surfaces, and higher radiochemical yields were obtained for (99m)Tc (97% ± 2%) and (68)Ga (94.6% ± 0.2%) under optimized pH conditions (pH = 5). The biomimetic NPs exhibited a good radiochemical and colloidal stability in phosphate-buffered saline and cell medium. In vitro studies demonstrated that the biomimetic NPs exhibited an enhanced cellular uptake and increased delivery of DOX to cancer cells, resulting in better chemotherapy than free DOX or pure NPs. Altogether, these findings indicate the potential of the developed platform for cancer treatment and diagnosis. MDPI 2023-10-22 /pmc/articles/PMC10610067/ /pubmed/37896267 http://dx.doi.org/10.3390/pharmaceutics15102507 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wen, Huang Poutiainen, Pekka Batnasan, Enkhzaya Latonen, Leena Lehto, Vesa-Pekka Xu, Wujun Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer |
title | Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer |
title_full | Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer |
title_fullStr | Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer |
title_full_unstemmed | Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer |
title_short | Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer |
title_sort | biomimetic inorganic nanovectors as tumor-targeting theranostic platform against triple-negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610067/ https://www.ncbi.nlm.nih.gov/pubmed/37896267 http://dx.doi.org/10.3390/pharmaceutics15102507 |
work_keys_str_mv | AT wenhuang biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer AT poutiainenpekka biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer AT batnasanenkhzaya biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer AT latonenleena biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer AT lehtovesapekka biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer AT xuwujun biomimeticinorganicnanovectorsastumortargetingtheranosticplatformagainsttriplenegativebreastcancer |